In this issue:
Capivasertib in hormone receptor+ advanced breast cancer
Dose-escalated simultaneous integrated boost RT in early breast cancer
Trastuzumab deruxtecan for HER2+ metastatic breast cancer
Disparities in locoregional recurrence in hormone receptor+, node–breast cancer
Endocrine therapy + trastuzumab-pertuzumab for hormone receptor+/ HER2+ early breast cancer
Longitudinal mammographic density changes and breast cancer risk
Alisertib ± fulvestrant in for endocrine-resistant advanced breast cancer
Initial vs. sequential salvage brain-directed treatment for 1–4 vs. 5–10 brain metastases
Impact of BMI on response to neoadjuvant targeted therapy in HER2+ breast cancer
Pembrolizumab + paclitaxel or flat-dose capecitabine for metastatic triple-negative breast cancer
Please login below to download this issue (PDF)